Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 12 May 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Although asset sales and cost reductions are expected to improve performance, operating profit, profit before tax and profit attributable to owners of the parent are expected to fall below the previous forecasts due to the anticipated recognition of impairment losses on PVDF and Kremezin manufacturing equipment.
Impairment loss on PVDF manufacturing equipment: approximately ¥34 billion; impairment loss on Kremezin manufacturing equipment: approximately ¥2.5 billion. The Kremezin-related amount will be recognized as an extraordinary loss of the same amount in the separate financial statements.
| Item | Details |
|---|---|
| Net Sales | ¥165,000 million → ¥161,000 million（△2.4%） |
| Operating profit | ¥14,000 million → ¥-17,900 million |
| Profit attributable to owners of the parent | ¥10,000 million → ¥-10,100 million |
| Net income per share | 249.82 yen and sen → -252.32 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 May 2025 |
| Previous-period results | Revenue: ¥162,015 million; operating profit: ¥9,428 million; profit before tax: ¥10,218 million; profit attributable to owners of the parent: ¥7,800 million; basic earnings per share: ¥149.67 |
| Reason for the revision | Although asset sales and cost reductions are expected to improve performance, operating profit, profit before tax and profit attributable to owners of the parent are expected to fall below the previous forecasts due to the anticipated recognition of impairment losses on PVDF and Kremezin manufacturing equipment. |
| Details and amount of extraordinary loss | Impairment loss on PVDF manufacturing equipment: approximately ¥34 billion; impairment loss on Kremezin manufacturing equipment: approximately ¥2.5 billion. The Kremezin-related amount will be recognized as an extraordinary loss of the same amount in the separate financial statements. |
| Dividend forecast revision | The year-end dividend will be reduced from ¥109.50 to ¥104.50 per share, and the annual dividend will be reduced from ¥219.00 to ¥214.00 per share. |
| Consolidated / non-consolidated | Consolidated / non-consolidated (standalone) |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The impairment losses on PVDF and Kremezin manufacturing equipment are expected to be recognized against a backdrop of delayed recovery in PVDF demand due to the downturn in the electric vehicle markets in Europe and the United States, contraction of the spherical adsorbent carbon market due to the emergence of new therapeutic drugs, and lower profitability of Kremezin following drug price reductions. Although asset sales and cost reductions are expected to improve performance, the company expects the impairment losses to weigh on results.